公开(公告)号：US20160287619A1

公开(公告)日：2016-10-06

申请号：US15183431

申请日：2016-06-15

Applicant: GLYCOM A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Salomonsson

IPC: A61K31/702 ,  A61K9/48 ,  A61K9/20 ,  A61K35/745 ,  A61K9/00

CPC classification number: A61K31/702 ,  A23L33/135 ,  A23L33/21 ,  A23V2002/00 ,  A61K9/2054 ,  A61K9/4841 ,  A61K35/745 ,  A61K2035/115 ,  A61K2300/00

Abstract: The invention relates to HMOs and compositions comprising thereof for reducing the risk of, preventing, or treating CVD and/or CDV associated pathological conditions or diseases in humans, particularly in overweight and obese humans.

Abstract translation: 本发明涉及包含它们的HMO及其组合物，用于降低人类，特别是超重和肥胖人类中的CVD和/或CDV相关病理状况或疾病的风险，预防或治疗。

公开(公告)号：US20160243139A1

公开(公告)日：2016-08-25

申请号：US15147115

申请日：2016-05-05

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Salomonsson

IPC: A61K31/702 ,  A61K31/7004

CPC classification number: A61K31/702 ,  A61K31/7004 ,  A61K45/06 ,  A61K2300/00

Abstract: The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for treating visceral pain.

Abstract translation: 本申请涉及含有一种或多种用于治疗内脏痛的人乳单糖或寡糖的合成组合物。

公开(公告)号：US12063949B2

公开(公告)日：2024-08-20

申请号：US17929905

申请日：2022-09-06

Applicant: GLYCOM A/S

Inventor： Bruce McConnell ,  Louise Kristine Vignæs

IPC: A23L33/00 ,  A23L33/135 ,  A61K31/702 ,  A61P31/04 ,  A61P31/12 ,  A23L33/12 ,  A23L33/19 ,  A23L33/195

CPC classification number: A23L33/40 ,  A23L33/135 ,  A61K31/702 ,  A61P31/04 ,  A61P31/12 ,  A23L33/12 ,  A23L33/19 ,  A23L33/195 ,  Y02A50/30 ,  A61K31/702 ,  A61K2300/00

Abstract: A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2′-fucosyllactose (2′FL), 3′-O-sialyllactose (3′-SL), 6′-O-sialyllactose (6′-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.

公开(公告)号：US11896604B2

公开(公告)日：2024-02-13

申请号：US17353730

申请日：2021-06-21

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7016 ,  A61P1/12

CPC classification number: A61K31/702 ,  A61K31/7016 ,  A61P1/12 ,  A61K2300/00

Abstract: The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.

公开(公告)号：US11833165B2

公开(公告)日：2023-12-05

申请号：US17341039

申请日：2021-06-07

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A23L33/21 ,  A23C9/20

CPC classification number: A61K31/702 ,  A23C9/206 ,  A23L33/21 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A23V2002/00 ,  A61K31/7004 ,  A61K2300/00 ,  A61K31/7012 ,  A61K2300/00 ,  A61K31/702 ,  A61K2300/00

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof.

公开(公告)号：US11684630B2

公开(公告)日：2023-06-27

申请号：US17099306

申请日：2020-11-16

Applicant: GLYCOM A/S

Inventor： Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61P25/22 ,  A61P25/24 ,  A61P1/00 ,  C07H3/06 ,  A23L33/15

CPC classification number: A61K31/702 ,  A23L33/15 ,  A61P1/00 ,  A61P25/22 ,  A61P25/24 ,  C07H3/06 ,  A61K31/702 ,  A61K2300/00

Abstract: A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

公开(公告)号：US20230000886A1

公开(公告)日：2023-01-05

申请号：US17780869

申请日：2020-11-27

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Dorthe Seitzberg ,  Ingvild Dybdrodt Amundsen

IPC: A61K31/702 ,  A61P1/12

Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in a lac-tose-intolerant, IBS patient; reintroducing a source of lactose into the diet of a lactose-intolerant, IBS patient while prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in the IBS patient; and/or reducing the severity and/or occurrence of non-gastrointestinal symptoms in a lactose-intolerant, IBS patient.

公开(公告)号：US11529365B2

公开(公告)日：2022-12-20

申请号：US17114850

申请日：2020-12-08

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K45/06 ,  A61P31/00 ,  A61P3/10 ,  A61P29/00 ,  A61K35/20 ,  A61K35/00

Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.

公开(公告)号：US11529364B2

公开(公告)日：2022-12-20

申请号：US17093337

申请日：2020-11-09

Applicant: GLYCOM A/S

Inventor： Emma Elison ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

公开(公告)号：US11491171B2

公开(公告)日：2022-11-08

申请号：US17026616

申请日：2020-09-21

Applicant: GLYCOM A/S

Inventor： Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A23L33/00 ,  A23L33/15 ,  A61P25/22 ,  A61P25/24

Abstract: A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.